Abstract
Cytomegalovirus (CMV) retinitis is the most common opportunistic infection of the eye in patients with HIV. It causes significant morbidity in immunocompromised patients, including transplant and HIV-infected patients. CMV is a DNA virus that infects around 40% of the population worldwide. Three patterns of active lesions have been described: hemorrhagic, brush fire, and granular. The mainstay of treatment in CMV retinitis is the reversal of immunodeficiency. Successful management of CMV retinitis requires not only HAART in HIV patients but also appropriate anti-CMV therapy such as systemic antivirals and adjunctive local treatment. Current available FDA-approved therapies for CMV retinitis include intravenous and intravitreal ganciclovir and foscarnet, intravenous cidofovir, and oral valganciclovir.
References
Carmichael A. Cytomegalovirus and the eye. Eye (Lond). 2012;26(2):237–40.
Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43(9):1143–51.
Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008;5:47.
Sugar EA, Jabs DA, Ahuja A, et al. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2012;153(6):1016.e5–24.e5.
Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol. 1996;114(7):821–7.
Jabs DA, Ahuja A, Van Natta ML, Lyon AT, Yeh S, Danis R. Long-term outcomes of cytomegalovirus retinitis in the era of modern antiretroviral therapy: results from a United States cohort. Ophthalmology. 2015;122(7):1452–63.
Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(1):231–3.
Mitchell SM, Membrey WL, Youle MS, Obi A, Worrell S, Gazzard BG. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol. 1999;83(6):652–5.
Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol. 2008;145(3):397–408.
D’Amico DJ, Talamo JH, Felsenstein D, Hirsch MS, Albert DM, Schooley RT. Ophthalmoscopic and histologic findings in cytomegalovirus retinitis treated with BW-B759U. Arch Ophthalmol. 1986;104(12):1788–93.
De Venecia G, Zu Rhein GM, Pratt MV, Kisken W. Cytomegalic inclusion retinitis in an adult. Arch Ophthalmol. 1971;86(1):44–57.
Murray HW, Knox DL, Green WR, Susel RM. Cytomegalovirus retinitis in adults. A manifestation of disseminated viral infection. Am J Med. 1977;63(4):574–84.
Pathanapitoon K, Tesavibul N, Choopong P, et al. Clinical manifestations of cytomegalovirus-associated posterior uveitis and panuveitis in patients without human immunodeficiency virus infection. JAMA Ophthalmol. 2013;131(5):638–45.
Ausayakhun S, Keenan JD, Ausayakhun S, et al. Clinical features of newly diagnosed cytomegalovirus retinitis in northern Thailand. Am J Ophthalmol. 2012;153(5):923.e1–31.e1.
Holland GN, Shuler JD. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol. 1992;110(10):1435–42.
Mansour AM. Cytomegalovirus optic neuritis. Curr Opin Ophthalmol. 1997;8(3):55–8.
Spaide RF, Vitale AT, Toth IR, Oliver JM. Frosted branch angiitis associated with cytomegalovirus retinitis. Am J Ophthalmol. 1992;113(5):522–8.
Aguilar Lozano LA, Gonzalez Dibildox A. Frosted branch angiitis associated with cytomegalovirus retinitis. Ophthalmology. 2016;123(3):645.
Kempen JH, Jabs DA, Dunn JP, West SK, Tonascia J. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch Ophthalmol. 2001;119(1):33–40.
Yen M, Chen J, Ausayakhun S, et al. Retinal detachment associated with AIDS-related cytomegalovirus retinitis: risk factors in a resource-limited setting. Am J Ophthalmol. 2015;159(1):185–92.
Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol. 1993;116(6):713–20.
Mathur G, Ratra D, Bhuibhar SS, Roy R. Clinical outcomes of retinal detachment surgery following cytomegalovirus retinitis in patients on highly active anti-retroviral therapy for acquired immune deficiency syndrome. Ocul Immunol Inflamm. 2015;23(5):400–4.
Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol. 2000;129(5):634–9.
Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology. 2006;113(4):684–94.
Huang G, Jiang Q, Li M, Lu Y, Wang Z. Retrospective study of cytomegalovirus retinitis complicated with acquired immunodeficiency syndrome. Int J Clin Exp Med. 2015;8(6):9537–42.
Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006;113(8):1432–40.
Song MK, Azen SP, Buley A, et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol. 2003;136(4):696–702.
Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. AIDS. 2005;19(7):735–8.
Jabs DA, Van Natta ML, Holland GN, Danis R. Studies of the ocular complications of ARG. Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome after initiating antiretroviral therapy. Am J Ophthalmol. 2017;174:23–32.
Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol. 1999;83(5):540–5.
El-Bradey MH, Cheng L, Song MK, Torriani FJ, Freeman WR. Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach. Retina. 2004;24(3):376–82.
Sugita S, Shimizu N, Watanabe K, et al. Use of multiplex PCR and real-time PCR to detect human herpes virus genome in ocular fluids of patients with uveitis. Br J Ophthalmol. 2008;92(7):928–32.
Harper TW, Miller D, Schiffman JC, Davis JL. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol. 2009;147(1):140.e2–7.e2.
Smith IL, Macdonald JC, Freeman WR, Shapiro AM, Spector SA. Cytomegalovirus (CMV) retinitis activity is accurately reflected by the presence and level of CMV DNA in aqueous humor and vitreous. J Infect Dis. 1999;179(5):1249–53.
Cunningham ET Jr, Wong RW, Takakura A, Downes KM, Zierhut M. Necrotizing herpetic retinitis. Ocul Immunol Inflamm. 2014;22(3):167–9.
Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004;111(12):2224–31.
Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia JA. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003;121(4):466–76.
Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA. 2000;283(5):653–7.
Jabs DA, Ahuja A, Van Natta M, Dunn JP, Yeh S. Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2013;120(6):1262–70.
Holbrook JT, Colvin R, van Natta ML, et al. Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis. Am J Ophthalmol. 2011;152(4):628.e1–37.e1.
Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597–638.
Biron KK. Antiviral drugs for cytomegalovirus diseases. Antivir Res. 2006;71(2–3):154–63.
Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995;333(10):615–20.
Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994;112(12):1531–9.
Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. 1997;337(2):83–90.
Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65(6):859–78.
Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346(15):1119–26.
Lalezari JP, Friedberg DN, Bissett J, et al. High dose oral ganciclovir treatment for cytomegalovirus retinitis. J Clin Virol. 2002;24(1–2):67–77.
Jacobson MA, O’Donnell JJ. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. J Acquir Immune Defic Syndr. 1991;4(Suppl 1):S11–5.
Studies of Ocular Complications of ARG, Group ACT. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326(4):213–20.
Jacobson MA, O’Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989;33(5):736–41.
Jacobson MA, Wulfsohn M, Feinberg JE, et al. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. AIDS. 1994;8(4):451–9.
Studies of Ocular Complications of ARGTACTG. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Ganciclovir Cidofovir Cytomegalovirus Retinitis trial. Am J Ophthalmol. 2001;131(4):457–67.
Walmsley S, Tseng A. Comparative tolerability of therapies for cytomegalovirus retinitis. Drug Saf. 1999;21(3):203–24.
Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42(9):2240–4.
Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;135(1):26–34.
Jabs DA, Martin BK, Ricks MO, Forman MS, Cytomegalovirus R, Viral Resistance Study G. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome. J Infect Dis. 2006;193(12):1728–37.
Martin BK, Ricks MO, Forman MS, Jabs DA, Cytomegalovirus R, Viral Resistance Study Group. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis. 2007;44(7):1001–8.
Chou S. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis. 2015;28(4):293–9.
Yeh S, Fahle G, Forooghian F, et al. Polymerase chain reaction-based ganciclovir resistance testing of ocular fluids for cytomegalovirus retinitis. Arch Ophthalmol. 2012;130(1):113–5.
Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis. 2001;184(12):1598–602.
Hoang QV, Simon DM, Kumar GN, Oh F, Goldstein DA. Recurrent CMV retinitis in a non-HIV patient with drug-resistant CMV. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):737–40.
Razonable RR, Emery VC, The Annual Meeting of the I. Management of CMV infection and disease in transplant patients. Herpes. 2004;11(3):77–86.
Gupta MP, Coombs P, Prockop SE, et al. Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion. Ophthalmic Surg Lasers Imaging Retina. 2015;46(1):80–2.
Rifkin LM, Minkus CL, Pursell K, Jumroendararasame C, Goldstein DA. Utility of leflunomide in the treatment of drug resistant cytomegalovirus retinitis. Ocul Immunol Inflamm. 2017;25(1):93–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Ung, C., Young, L.H. (2020). CMV Retinitis. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-90495-5_11-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-90495-5_11-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-90495-5
Online ISBN: 978-3-319-90495-5
eBook Packages: Springer Reference MedicineReference Module Medicine